2seventy Bio stops enrolling patients in blood cancer therapy study

2Seventy Bio

25/09/2024 11:13

Sept 25 (Reuters) - 2seventy bio  TSVT.O  on Wednesday
said it would discontinue enrolling new patients in the
late-stage study for its cell therapy to treat newly diagnosed
myeloma, which is a type of blood cancer.

 (Reporting by Kashish Tandon in Bengaluru; Editing by Abinaya
Vijayaraghavan)
 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))